Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM4 | O15151 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 3/20 | 0.52 |
| ▸ | ACE | P12821 | 4/20 | 0.50 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | CPA1 | P15085 | 2/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 2/20 | 0.50 |
| ▸ | CTSL | P07711 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.50 |
| ▸ | CTSS | P25774 | 1/20 | 0.50 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.48 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.48 |
| ▸ | CASP3 | P42574 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29385767 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29370428 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL1514663 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29406248 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29410226 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL3736523 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29400401 | 1.00 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL29754274 | 0.97 | MDM4 (0.52) | MDM4TP53ACEMMECPA1 | |
| SCHEMBL8248794 | 0.92 | MDM4 (0.49) | MDM4TP53PTPN1MDM2CASP3 | |
| SCHEMBL15697341 | 0.90 | CTSB (0.49) | MDM4TP53CTSLCTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112961173-B | Prostate specific membrane antigen targeted molecular probe, preparation method and application thereof | 江南大学附属医院 | 2022-04-19 | — | — | CN | claimed |
| CN-112961173-A | Prostate specific membrane antigen targeted molecular probe, preparation method and application thereof | 江南大学附属医院 | 2021-06-15 | — | — | CN | claimed |
| EP-4727654-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727655-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| EP-4727653-A1 | DLL3 TARGETING PEPTIDES AND CONSTRUCTS THEREOF | Mariana Oncology Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103447-A1 | METHODS FOR PREPARING PSMA CONJUGATES | ENDOCYTE, INC. | 2026-04-16 | — | — | US | disclosed |
| US-12576154-B2 | Conjugates of PSMA-binding moieties with cytotoxic agents | PHILOCHEM AG (CH) | 2026-03-17 | — | — | US | disclosed |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | NOVARTIS AG (CH) | 2026-01-08 | — | — | US | disclosed |
| EP-4663652-A1 | SYNTHESIS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS | Novartis AG (CH) | 2025-12-17 | — | — | EP | disclosed |
| US-12473265-B2 | Methods for preparing PSMA conjugates | ENDOCYTE, INC. (US) | 2025-11-18 | — | — | US | disclosed |
| US-20030050248-A1 | Novel amino acid and peptide inhibitors of Staphylococcus virulence | PANORAMA RESEARCH, INC. | 2003-03-13 | — | — | US | disclosed |
| EP-1280801-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-02-05 | — | — | EP | disclosed |
| EP-1261362-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | Intermune, Inc. (US) | 2002-12-04 | — | — | EP | disclosed |
| WO-2002063299-A1 | LOW AFFINITY SCREENING METHOD | GRAFFINITY PHARMACEUTICALS AG (DE) | 2002-08-15 | — | — | WO | disclosed |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | HOFFMANN-LA ROCHE INC. | 2001-12-27 | — | — | US | disclosed |
| WO-2001083478-A2 | HYDANTOIN-CONTAINING GLUCOKINASE ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2001-11-08 | — | — | WO | disclosed |
| WO-2001058471-A2 | NOVEL AMINO ACID AND PEPTIDE INHIBITORS OF STAPHYLOCOCCUS VIRULENCE | INTERMUNE, INC. (US) | 2001-08-16 | — | — | WO | disclosed |
| EP-1054882-A1 | CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Aventis Pharma S.A. (FR) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999041248-A1 | CONDENSED HETEROCYCLIC SYSTEM DERIVATIVES, PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | AVENTIS PHARMA S.A. (FR) | 1999-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260103447-A1 | METHODS FOR PREPARING PSMA CONJUGATES | PSMA1, PSMA3, PSMA2 | MDM4 1821/4885TP53 1506/4885ACE 3335/4885 |
| US-12576154-B2 | Conjugates of PSMA-binding moieties with cytotoxic agents | PCNA, ENPEP, PSMA3 | MDM4 1911/4885TP53 880/4885ACE 3096/4885 |
| US-20260007784-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | KLK3, PSMA1, ACP3 | MDM4 3460/4885TP53 308/4885ACE 2910/4885 |
| US-20010056191-A1 | Hydantoin-containing glucokinase activators | GCK, GCKR, HK2 | MDM4 4717/4885TP53 4711/4885ACE 1020/4885 |
| US-20260007785-A1 | USE OF LABELED INHIBITORS OF PROSTATE SPECIFIC MEMBRANE ANTIGEN (PSMA), AS AGENTS FOR THE TREATMENT OF PROSTATE CANCER | PSMA1, ACP3, FOLH1 | MDM4 3286/4885TP53 286/4885ACE 3374/4885 |
| US-12473265-B2 | Methods for preparing PSMA conjugates | FOLH1, PSMA6, PSMA1 | MDM4 2577/4885TP53 203/4885ACE 1467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.